BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma

被引：0
|
作者：
Rashid, Aliya [1 ,2 ,3 ]
Wesson, William [2 ,4 ,5 ]
Lutfi, Forat [1 ,5 ]
Mushtaq, Muhammad Umair [5 ]
McGuirk, Joseph P. [5 ,6 ]
Abdallah, Al-Ola
Cui, Wei [7 ]
Ahmed, Nausheen [5 ]
机构：
[1] US Myeloma Innovat Res Collaborat USMIRC, Kansas City, KS USA
[2] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Ctr Canc, Kansas City, MO USA
[3] Univ Kansas, Med Ctr, Internal Med, Kansas City, KS USA
[4] Univ Kansas, Sch Med, Kansas City, KS USA
[5] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Kansas City, KS USA
[6] Univ Kansas, Med Ctr, Westwood, KS USA
[7] Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182126
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] B- Cell Maturation Antigen (BCMA) Re-Emergence and Relapse Patterns Post-BCMA-Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Multiple Myeloma
    Wesson, William
    Cui, Wei
    Mushtaq, Muhammad
    Bansal, Rajat
    Singh, Anurag K.
    Hoffmann, Marc
    Tun, Aung M.
    Balusu, Ramesh
    Abdelhakim, Haitham
    Abhyankar, Sunil H.
    McGuirk, Joseph P.
    Shune, Leyla O.
    Abdallah, Al-Ola
    Ahmed, Nausheen
    BLOOD, 2022, 140 : 12781 - 12783
  • [2] BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma
    Yang, Jinrong
    Zhou, Weilin
    Li, Dan
    Niu, Ting
    Wang, Wei
    CANCER LETTERS, 2023, 553
  • [3] Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease
    Dima, Danai
    Davis, James A.
    Rashid, Aliya
    Rice, Mikhaila
    DeJarnette, Shaun
    Shune, Leyla
    Khouri, Jack
    Raza, Shahzad
    McGuirk, Joseph P.
    Anwer, Faiz
    Ahmed, Nausheen
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2023, 142
  • [4] Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy
    Soomro, Mohammad Ahsen
    Atrash, Shebli
    Rashid, Aliya
    Wesson, William
    Hashmi, Hamza
    Afrough, Aimaz
    Skikne, Barry S.
    Lutfi, Forat
    Mushtaq, Muhammad Umair
    Abdallah, Al-Ola
    Ahmed, Nausheen
    BLOOD, 2023, 142
  • [5] Chimeric antigen receptor T-cell therapy for multiple myeloma
    Wang, Zehua
    Chen, Chen
    Wang, Lei
    Jia, Yongxu
    Qin, Yanru
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [6] Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
    Hosen, Naoki
    CANCERS, 2019, 11 (12)
  • [7] Chimeric antigen receptor T-cell therapy for multiple myeloma
    Hosen, Naoki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (04) : 530 - 534
  • [8] Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma
    Atrash, Shebli
    Ali, Syed Abbas
    Usmani, Saad Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (01): : 21 - 34
  • [9] Chimeric antigen receptor T-cell therapy for multiple myeloma
    Naoki Hosen
    International Journal of Hematology, 2020, 111 : 530 - 534
  • [10] Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy
    Shen, Ying
    Liu, Jie
    Wang, Baiyan
    Zhang, Yilin
    Xu, Yan
    Wang, Xiaman
    Jia, Yachun
    Meng, Xin
    Wang, Xugeng
    Fan, Xiaohu
    He, Aili
    Zhao, Wanhong
    CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2023, 71 (02)
12345